Drawing for ACELLYTRON THERAPEUTICS

USPTO serial 79389188

ACELLYTRON THERAPEUTICS

Reviewed by CopyMark Law Group

Reg. 8081479Status 700Registered
Filing date
Status date
Registration date
Dec 30, 2025
Examiner
THOMAS, JULIE
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ACELLYTRON THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael T. Smith

Michael T. Smith Birch Stewart Kolasch & Birch, LLP2600 Park Tower Drive, Suite 600Vienna, VA 22180United States

Goods and services

ClassDescriptionStatusFirst use
005Chemico-pharmaceutical preparations for the treatment of autoimmune, neurodegenerative, metabolic, viral and infectious diseases, and for the treatment of cancer; biochemical medicines for the treatment of autoimmune, neurodegenerative, metabolic, viral and infectious diseases, and for the treatment of cancer; vaccine preparations; influenza vaccine; chemotherapeutics; stem cells for medical purposes; medicines for human purposes for the treatment of autoimmune, neurodegenerative, metabolic, viral and infectious diseases, and for the treatment of cancer; drugs for medical purposes, namely, medicines for the treatment of autoimmune, neurodegenerative, metabolic, viral and infectious diseases, and for the treatment of cancer; pharmaceutical preparations for the treatment of autoimmune, neurodegenerative, metabolic, viral and infectious diseases, and for the treatment of cancer; drugs for treatment of cancer; medical preparation for treating diseases and disorders related to the immune system; biological agent, namely, biological preparations for treating cancer; pharmaceutical preparations for the prevention and treatment of cancer; living cells for medical use; medical cell inhibitor for inhibiting the growth of cancer cells; reagents for medical purposes; anticancer agent; diagnostic reagents for medical purposes; pharmaceutical preparations, namely, tumor suppressor; cells for medical use; dietetic infusions, sugar, foods, and beverages adapted for medical use; biological preparations for veterinary purposes for the treatment of autoimmune, neurodegenerative, metabolic, viral and infectious diseases, and for the treatment of cancerACTIVE—
035Online advertising on a computer network; advertising services; publicity agents; dissemination of advertising and advertising matter in the nature of flyers, prospectuses, brochures, leaflets and samples; providing commercial information and advice for consumers in the choice of products and services; organization of exhibitions and trade fairs for commercial or advertising purposes; import-export agency services; marketing; sponsorship search; retail store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; wholesale store services for pharmaceutical, veterinary and sanitary preparations and medical suppliesACTIVE—
042Research and development of new products for others; technological research in the field of chemical and biological medicaments; chemical analysis; biochemical research and analysis; research and development in the field of pharmaceutical preparations; medical research service; research and development services in the field of antibodies; stem cell research services; medical research; medical and scientific research, namely, conducting clinical trials for others; biological research; computer programming in the field of medical aspectsACTIVE—
044Preparation of prescriptions by pharmacists; stem cell therapy services; medical clinic services; providing medical information; DNA screening for medical purposes; medical analysis services for the diagnosis of cancer; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical screening; health care; medical assistanceACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 23, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jul 6, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jul 6, 2026FIMPFINAL DISPOSITION PROCESSED—
Mar 30, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Dec 30, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Dec 30, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 11, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 11, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 5, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 9, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 10, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 10, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 10, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 1, 2025RFNTREFUSAL PROCESSED BY IB—
Jul 26, 2025OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jul 15, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jul 15, 2025RFRRREFUSAL PROCESSED BY MPU—
Jul 15, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jul 7, 2025OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 7, 2025OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jun 27, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 27, 2024RFWRNON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW—
Jun 27, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 26, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 26, 2024DOCKASSIGNED TO EXAMINER—
Feb 16, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 12, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 10, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance